Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
doi:10.1523/JNEUROSCI.1910-15.2015 Increased tissue concentrations of lactate stemming from localised mitochondrial dysfunction also promote a local inflammatory environment through triggering the release of cytokines IL-1B and TNF-a, along with increasing NF-KB-dependent inflammatory gene expression
AOD-9604 Pharmacokinetics & Metabolism Absorption & Distribution AOD-9604 exhibits unusual pharmacokinetic properties for a peptide, demonstrating activity via multiple administration routes in preclinical models: Oral bioavailability confirmed in pig and rodent studies, an uncommon characteristic for peptide compounds Rapid systemic distribution following intraperitoneal administration in mice (15-30 minutes) Following IV administration in pigs, AOD-9604 and degradation fragments appeared rapidly in plasma Oral administration showed slower kinetics but similar degradation product profiles Distribution studies using radiolabeled peptide (C-14-AOD9604) in rats revealed: Elevated concentrations in pineal body and thyroid tissues Distribution to all non-CNS tissues examined Minimal penetration of blood-brain barrier Tissue-specific accumulation patterns suggesting potential targeting mechanisms Metabolism & Elimination The metabolic fate of AOD-9604 involves rapid degradation through sequential N-terminal amino acid removal,: Plasma half-life of approximately 3 minutes following IV administration in pigs (compared to 21 minutes for full-length growth hormone) Sequential amino-terminal truncation represents the primary degradation pathway Principal metabolites identified in vivo include -2 amino acid and -3 amino acid fragments These truncated fragments retain some reduced in vitro anti-lipogenic activity A significant pharmacokinetic paradox exists: despite rapid plasma clearance (peptide undetectable at 56 minutes in spiked plasma studies), biological effects on body weight and fat metabolism persist for hours to days
Call (808) 201-2343 - Honolulu Office or (808) 201-2343 - Kailua Kona Office to schedule your initial consultation at the most convenient location
GLP-1 receptor agonist medications for obesity and type 2 diabetes treatment: a rapid review of changes in eating behaviors and eating disorder risk
Its a nuanced question, and understanding the ins and outs of how our bodies absorb this vital vitamin is key to finding the right answer for you
[PMID: 34116443] PubMed record related to this compound for laboratory literature review
